A Phase 1 Trial Assessing Pharmacokinetics and Safety of CAM2056 (Semaglutide Subcutaneous Depot)
This research study is about a new way to deliver a medicine called semaglutide, which is already used to help with body weight. The new version, called CAM2056, is designed to be a 'depot' which means it might be given less often. This is a very early stage study, called a Phase 1 trial, meaning it's the very first time this new form of the medicine is being given to people. The main goals are to understand how the medicine travels through the body, how long it stays there, and to check if it's safe. It's open to adult volunteers, aged 18 and older, regardless of their gender. This study is an important step to see if this new method of giving the medicine could be useful in the future for managing weight.
At a glance
What is this study about?
This study is about exploring a new version of a medicine called semaglutide, known as CAM2056. Semaglutide is a medicine that's already used to help people manage their body weight. The key difference in this study is that CAM2056 is designed to be a 'subcutaneous depot'. This means it's intended to be given as an injection under the skin, but in a way that the medicine slowly releases over time. This could mean fewer injections compared to current versions of semaglutide.
This is a very early stage of research, called a Phase 1 clinical trial. This means it's the first time this specific new formulation of the medicine is being given to people. The main reasons for this study are to see how the medicine behaves in the human body – for example, how much of it gets into the blood, how long it stays there, and how the body handles it. Researchers also want to find out if it's safe and if people can tolerate it well.
The findings from this study are crucial. If CAM2056 proves to be safe and shows promising signs of working well within the body, it could potentially become a new option for managing body weight in the future. It’s a foundational step to understand if this new way of giving the medicine is worth further investigation in larger studies.
Key takeaways
- This is an early study of a new form of a weight management medicine.
- It aims to check safety and how the medicine works in the body.
- The new medicine is designed for slower release after an injection under the skin.
- Participants must be adults (18 years or older), both men and women.
- It's a foundational step to see if this new approach could be useful for body weight management.
Who may be eligible?
To be considered for this study, you need to be an adult, aged 18 years or older. There is no upper age limit, meaning older adults can also take part. The study is open to both men and women.
Since this is a very early study looking at a new version of a medicine, there will be other very specific health checks to make sure it's safe for you to take part. This usually involves being generally healthy and not having certain long-term health conditions or taking particular medications that might interfere with the study medicine.
The research team will carry out a thorough medical review to determine if you meet all the necessary requirements to join. It’s important to share your full medical history so they can make the best decision for your safety.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Are you generally healthy?
- Are you comfortable receiving injections?
- Are you able to attend regular clinic visits?
- Are you willing to share your full medical history?
What does participation involve?
If you decide to take part in this study, you would first have a screening visit to check if you meet all the requirements. This would involve medical tests and a review of your health history. If you qualify, you would receive the study medicine, CAM2056, as an injection under the skin.
You would need to attend several visits to the clinic or study site. During these visits, doctors and nurses would monitor your health carefully, take blood samples to see how the medicine is working in your body, and ask about any side effects you might be experiencing. These visits might be more frequent at the beginning and then become less frequent over time. The total duration of your participation in the study, including all visits and follow-up, will be clearly explained to you by the study team.
Potential risks and benefits
Locations (1)
- —UnverifiedGermany
Common questions
What is semaglutide?
Semaglutide is a medicine that helps manage body weight, often by affecting appetite and how your body uses sugar.
What does 'Phase 1' mean?
Phase 1 means this is the very first time this new form of the medicine is being tested in people. It mainly checks if it's safe and how the body handles it.
What is a 'subcutaneous depot'?
It means the medicine is given as an injection under the skin in a way that it slowly releases over a period of time, potentially leading to fewer injections.
Will I know if I'm getting the actual medicine?
In some studies, people don't know if they're getting the active medicine or a dummy medicine, but the study team will explain the details of this specific trial.
Are there any costs for me to participate?
No, you should not have to pay to participate in a clinical trial. The study usually covers all research-related costs.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.